Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Good start today. I was watching for the whole day yesterday and I just had a feeling. I posted on twitter for some coverage. Got our chart looked at and also highlighted the company on a few groups I am in. I think I will just stick to news articles for the time being. Look forward to hearing from our CEO!
# Trades 6
Vol. Sold 0
Sold Value £0.00
Vol. Bought 831,849
Bought Value £13,856.02
Just topping up. Got 100000 just now. Let's see how we go today. Happy Friday anyway
https://twitter.com/hashtag/EOG?src=hashtag_click
https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-bulletin-board-heroes-february-9-23f3239/
I think the 628010 was a buy.
I am waiting for the SP to settle before topup
I noticed a few big trades at close.
01-Feb-22 16:20:24 1.9775 650,000 Unknown* 1.90 2.10 12.85k O
31-Jan-22 13:41:30 1.95 1,325,000 Unknown* 1.90 2.10 25.84k O
01-Feb-22 16:21:15 2.00 200,000 Unknown* 1.90 2.10 4,000 O
Are they buys or sells? the dates are strange
This morning I bought 200k at 1.99.... Its my first time buying in so I will keep an eye for topping up and building my position.
Here is the link to hVIVO webpage where you can find out more information on all of our Challenge models (Influenza, HRV, RSV, Asthma, COPD and Cough).
Plus keep up to date on news, media and events.
https://hvivo.com/
Whats wrong with the share price?
I do not understand how a company that is rolling in cash and have so much positives has a sp like this. Its mad!
HRA sign off? IS THIS THE ONE???
https://twitter.com/Jigger93609885/status/1483769467297574913?t=7EpEQPVCNCNDhVh7qfIE3g&s=19
Longer term, challenge studies can be instrumental for accelerating development of current vaccine candidates. With the availability of effective vaccines, placebo groups in phase 3 studies will soon no longer be an ethically viable option. Head-to-head human challenge vaccine studies can rapidly provide data on the efficacy of new vaccines, new formulations of existing vaccines, or efficacy against viral variants. To mitigate the inherent risks involved, the UK COVID Challenge Study is being conducted in a low-risk population, namely those 18–30 years of age, in whom severe outcomes are rare and symptoms typically resolve within months. Chiu also stressed the importance of extensive public and participant involvement and engagement. Recent surveys and focus groups in the UK show strong support for a human challenge study.
NYAS Publications 14/01/22 https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/nyas.14739#.YebbGAUpW4I.twitter UK HCS programme ongoing. ‘Head to head’ trials planned. Recent survey/focus groups show ‘strong support’ for trials to commence.
Can we give 2 fingers to the seller now?
If it develops a vaccine that shields people and of course the economy, then it would be time well spent... What if it was not done and Delta came back in a few years?? Best to leave no stone un-turned.
https://blogs.imperial.ac.uk/doid-staff/2022/01/12/funding-successes-december-2021/
17-Jan-22 08:20:50 21.00 500,000 Buy* 105.00k O
Nice.
Poolbeg Pharma
Poolbeg Pharma (AIM:POLB), which listed in July, aspires to become a one-stop shop for big pharma to find products primed for development and commercialisation. Spun out from Open Orphan, covered above, Poolbeg aims to commercialise the clinical data repository its parent company has built up through 20 years of challenge trials testing how the body’s immune system can be boosted to overcome a range of viruses.
Poolbeg’s flagship asset POLB 001 is a ‘Phase II-ready p38 MAP Kinase inhibitor’ that promises an efficient treatment for inflammation in patients with severe influenza. Current treatments disrupt viral replication but do not directly address these hyperinflammatory episodes: POLB 001, which has passed Phase I trials confirming its safety for human use, opens new option to the $800m influenza market. It also offers the potential for applications beyond influenza, including certain coronavirus cases. Poolbeg is working towards Phase II trials, at which point it intends to license the treatment to a large pharmaceutical firm. The company intends to commence the Phase Ib human challenge study of POLB 001 in June next year. European patents have already been secured, and US patent assessments are underway.
Poolbeg also offers the PredictVital Biomarker Platform, designed identify the risk of severe disease before the onset of symptoms, reducing the need for antiviral treatments and their possible side-effects. Another service, the Vaccine Discovery Platform, will allow users to search the Open Orphan repository for new treatments based on reengineering of the immune system. Poolbeg continues to analyse the repository for new candidates for clinical development. Earlier this month the company signed terms for the development of an oral vaccine delivery platform with AnaBio Technologies, with a full licence and collaboration agreement to follow.
The company’s IPO plans outlined a ‘capital light clinical model’ designed to allow it to bring products to market quickly and cheaply ‘where they can potentially be monetised through licensing to or partnering with Big Pharma companies’.Poolbeg went public on 19 July, raising £25m.
The company is currently priced at 9.6p, a little down on its IPO price of 10p. Tapping into a growing market with its suite of discovery platforms, Poolbeg Pharma is one to watch in 2020.